Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

Not intended for UK Media OCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, without increasing ISTH major bleeding rate, compared to placebo with antiplatelet therapy OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor Bayer will globally engage with health authorities in preparation … [Read more…]

Transmural Systems Receives FDA 510(k) Clearance for Telltale

ANDOVER, Mass.–(BUSINESS WIRE)–Transmural Systems, a leader in pioneering electrosurgical structural heart therapies, obtained 510(k) clearance from the United States Food and Drug Administration (FDA) for TELLTALE – the first and only cleared and dedicated electrosurgical guidewire system to prevent coronary obstruction in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) for both native aortic stenosis and … [Read more…]

ATCC Welcomes National Security Commission on Emerging Biotechnology for the Capital Region Stop of the Biotech Across America Roadshow

ATCC, industry, government, advocacy, and academic leaders met with NSCEB Commissioners for pivotal discussions on the critical role of authenticated biomaterials in a secure and resilient bioeconomy MANASSAS, Va.–(BUSINESS WIRE)–#Biomanufacturing—ATCC, the world’s premier private, non-profit biological resources and standards organization, hosted an event today, Empowering the Future of Biotechnology Through Trusted Science, with the National … [Read more…]

Graft Versus Host Disease (GvHD) Treatment Market Trends, Strategies and Investment Opportunities 2025-2030 – CAR-T and Cell Therapy Advancements Generate New Demand for GvHD Management Solutions – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Graft Versus Host Disease (GvHD) Treatment – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market for Graft Versus Host Disease (GvHD) Treatment was valued at US$2.9 Billion in 2024 and is projected to reach US$4.5 Billion by 2030, growing at a CAGR of 7.3% from 2024 to 2030. … [Read more…]

Diagnostic Labs Market Analysis and Forecast Report, 2020H-2030F with Analyst Recommendations – Adopt Advanced Technologies for Differentiation / Expand Into Emerging Markets – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diagnostic Labs Market With Impact Analysis of US Tariffs (2025 Edition)” report has been added to ResearchAndMarkets.com’s offering. The global Diagnostic Labs Market is driven by several key factors. The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions creates a growing need for diagnostic tests, particularly for early detection … [Read more…]

beBright Appoints Kyle Clay as Chief Executive Officer to Lead Next Phase of Integrated Growth

MINNEAPOLIS–(BUSINESS WIRE)–#CEOAnnouncement—beBright, a doctor-founded, doctor-led dual-specialty support organization focused on integrated pediatric and orthodontic care, today announced the appointment of Kyle Clay as Chief Executive Officer. Kyle, who most recently served as Chief Operating Officer, will lead beBright’s next phase of organic growth and continue advancing the company’s mission to deliver exceptional experiences and life-changing … [Read more…]

Peanut Allergy Treatment Market Trends Analysis Report 2025-2033: Product Pipeline Expansion, Rising Disease Burden, Advanced Drug Delivery, and Strategic Player Initiatives Propel Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peanut Allergy Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antihistamines, Epinephrine, Immunotherapies), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 – 2033” report has been added to ResearchAndMarkets.com’s offering. The global peanut allergy treatment market size is expected to reach USD 1.46 billion by … [Read more…]

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will … [Read more…]

Hyperfine, Inc. to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans to present at the upcoming Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4th at 8:10 am Eastern Time (ET). A live audio … [Read more…]

QSimulate Announces New Financing and Latest Generation of Quantum Technology for Drug Discovery

Boston startup – known for pioneering quantum chemistry reformulations to simulate complex drug-protein interactions at a subatomic level with high precision and 1000x faster – raises financing and introduces QUELO v2.3 BOSTON–(BUSINESS WIRE)–QSimulate (www.qsimulate.com) today announced an additional round of seed financing that will bring its total funding to date to over $11 million from … [Read more…]